Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,500 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06683885 | A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 80 | Mingzhi ZhangOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06644118 | A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) | recruiting | Phase 1 | 58 | Zhejiang UniversityOTHER | 1 | Nov 8, 2024 |
| clinicaltrials |
| NCT06678282 | JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06608732 | Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04561557 | Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System(CARTinNS) | recruiting | Early Phase 1 | 36 | Tongji HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06659276 | Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma(MMR-PET-22-04) | recruiting | — | 83 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05348213 | Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma(R-ICE+X) | recruiting | Phase 2 | 76 | Ruijin HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05806580 | Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 4 | 8 | Ruijin HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06589089 | Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy | recruiting | Phase 2 | 18 | Ruijin HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06647940 | Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial) | recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05546723 | LMY-920 for Treatment of Relapsed or Refractory Myeloma(LMY-920-002) | recruiting | Phase 1 | 30 | Luminary TherapeuticsINDUSTRY | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06644443 | BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04070040 | Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) | recruiting | Phase 2 | 21 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05299424 | A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 48 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06609304 | Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma(axi-cel) | recruiting | Phase 4 | 20 | Zhengzhou UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06635330 | Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL | recruiting | Phase 1 / Phase 2 | 5 | Kara Yakhteh Tajhiz Azma CompanyNETWORK | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06418477 | Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD | recruiting | Phase 2 | 20 | Peking University People's HospitalOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06238648 | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | recruiting | Phase 2 | 120 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06581640 | Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 5 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06607419 | Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia(BBClean) | recruiting | Phase 2 / Phase 3 | 90 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04332822 | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma(POLAR BEAR) | recruiting | Phase 3 | 300 | Nordic Lymphoma GroupNETWORK | 7 | Sep 19, 2024 | clinicaltrials |
| NCT06450067 | Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia | recruiting | — | 200 | Juventas Cell Therapy Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06503263 | Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL | recruiting | Phase 2 | 240 | Navy General Hospital, BeijingOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06539832 | Intestinal Flora and Immunity in Monoclonal Gammopathy Patients | recruiting | — | 300 | Zhujiang HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06593145 | CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms(CARLA) | recruiting | Phase 1 | 6 | FamiCordTxINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06341556 | A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma | recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT06553352 | Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma | recruiting | Phase 2 | 39 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06047197 | Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 25 | Beijing Yongtai Ruike Biotechnology Company LtdINDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06569485 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients | recruiting | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT02131753 | Therapy Optimisation for the Treatment of Hairy Cell Leukemia | recruiting | Phase 2 / Phase 3 | 210 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05255354 | Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy | recruiting | — | 300 | Adaptive BiotechnologiesINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06566807 | Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 51 | Huai'an First People's HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06187441 | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)(HOVON174MM) | recruiting | Phase 3 | 599 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06554561 | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06554626 | Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL | recruiting | Phase 2 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06541860 | DAratumumab and REvlimid REfractory MM | recruiting | — | 100 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06522555 | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma | recruiting | Phase 3 | 100 | Ruijin HospitalOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06271252 | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | recruiting | Phase 1 | 81 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | recruiting | Phase 1 / Phase 2 | 68 | University Hospital HeidelbergOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06478472 | Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy | recruiting | N/A | 36 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06520176 | Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients | recruiting | Phase 3 | 99 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06521255 | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 3 | 244 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06517004 | An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06515262 | Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | recruiting | N/A | 10 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06287398 | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | recruiting | Phase 2 | 39 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06513234 | Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas | recruiting | Phase 2 | 45 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06505369 | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients(TALTEC) | recruiting | Phase 2 | 50 | North Estonia Medical CentreOTHER | 3 | Jul 17, 2024 | clinicaltrials |
| NCT06503107 | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | recruiting | Phase 3 | 78 | Ruijin HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT05636787 | Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients(TreoMel) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 12, 2024source: clinicaltrials